EANS-News: Intercell AG / Intercell launches Level I ADR program in the Unites States

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Wien (euro adhoc) - Vienna (Austria), May 7, 2009 - Intercell AG announced today
that it has launched a sponsored Level I American Depositary Receipt (ADR)
facility in the United States. The Bank of New York Mellon has been appointed as
the Company's depositary bank for this facility and will start issuing U.S.
dollar denominated ADRs as of today. Each ADR will represent one Intercell AG
ordinary share.

Intercell's shares are listed and will continue to trade on the Vienna Stock
Exchange (VSE). To enhance trading of its ADRs, Intercell has applied to have
its ADRs quoted on the OTCQX International market, a leading electronic listing
and disclosure platform for qualified foreign issuers on the U.S.
over-the-counter (OTC) securities market. Intercell ADRs will trade under the
symbol "INRLY".

"The ADR program is an additional step to expand our reach to investors in the
United States," said Reinhard Kandera, Intercell's Chief Financial Officer. "We
have recently received U.S. approval for our first product - IXIARO, a novel
vaccine against Japanese Encephalitis, - we have a sizable U.S. research and
development operation in Gaithersburg, Maryland, and our advanced clinical
pipeline in the area of hospital-acquired infections and patch vaccines has
received a lot of attention from U.S. healthcare equity investors. The launch of
an ADR program and the OTCQX quotation are logical next steps to further develop
our relationship with current and future U.S. shareholders."

About ADRs

An American Depositary Receipt (ADR) is a negotiable U.S. security that
represents a company's publicly traded equity or debt. Depositary Receipts are
created when a broker purchases a non-U.S. company's shares on its home stock
market and delivers the shares to the depositary's local custodian bank, and
then instructs the depositary bank, such as The Bank of New York Mellon, to
issue Depositary Receipts. In addition, Depositary Receipts may also be
purchased in the U.S. secondary trading market. Level I ADRs may trade freely
just like any other security in the over-the-counter (OTC) market. More
information on ADRs is available at www.adrbnymellon.com.

About OTCQX

OTCQX provides a gateway to U.S. securities markets for international companies
that are listed on a qualified non-U.S. exchange and provide ongoing disclosure
in English to U.S. investors. More importantly, OTCQX distinguishes the
reputable international issuers from the 9,000 over-the-counter (OTC) securities
traded in the United States. OTCQX quotation is not a stock exchange listing,
and issuers are not subject to regulatory requirements such as Sarbanes Oxley
compliance or U.S.-GAAP reporting. For more information about OTCQX, visit
www.otcqx.com.

Further inquiry note:
Intercell AG
Lucia Malfent
Head of Corporate Communications
Tel. +43 1 20620-1303
[email protected]

end of announcement euro adhoc
--------------------------------------------------------------------------------

emitter: Intercell AG
Campus Vienna Biocenter 3
A-1030 Wien
phone: +43 1 20620-0
FAX: +43 1 20620-800
mail: [email protected]
WWW: www.intercell.com
sector: Biotechnology
ISIN: AT0000612601
indexes: ATX Prime, ATX
stockmarkets: official market: Wiener Börse AG
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | CNE

print